Thats the thing maybe they didn't want it. Are they really that stupid? Maybe the tail is waging this dog. I mean seriously how good was this short.
As for result these results seem favourable against the control and in a vacuum maybe they could sell it but I don't think anyone will want to take this drug for value so this is over for Cantixil. Its really a one trick pony now. I mean 5 % above control is favourable. I think immuontherapy comes in at around 20% so this is not so great from what I can see but I'm not a scientist.
Good luck.
- Forums
- ASX - By Stock
- KZA
- Ann: Cantrixil last patient visit
Ann: Cantrixil last patient visit, page-15
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online